全文获取类型
收费全文 | 4129篇 |
免费 | 290篇 |
国内免费 | 13篇 |
专业分类
耳鼻咽喉 | 61篇 |
儿科学 | 220篇 |
妇产科学 | 69篇 |
基础医学 | 567篇 |
口腔科学 | 109篇 |
临床医学 | 252篇 |
内科学 | 962篇 |
皮肤病学 | 103篇 |
神经病学 | 289篇 |
特种医学 | 192篇 |
外科学 | 597篇 |
综合类 | 11篇 |
一般理论 | 1篇 |
预防医学 | 428篇 |
眼科学 | 49篇 |
药学 | 237篇 |
中国医学 | 35篇 |
肿瘤学 | 250篇 |
出版年
2023年 | 25篇 |
2022年 | 52篇 |
2021年 | 141篇 |
2020年 | 77篇 |
2019年 | 132篇 |
2018年 | 155篇 |
2017年 | 102篇 |
2016年 | 91篇 |
2015年 | 110篇 |
2014年 | 152篇 |
2013年 | 180篇 |
2012年 | 289篇 |
2011年 | 277篇 |
2010年 | 154篇 |
2009年 | 135篇 |
2008年 | 230篇 |
2007年 | 219篇 |
2006年 | 235篇 |
2005年 | 181篇 |
2004年 | 181篇 |
2003年 | 188篇 |
2002年 | 164篇 |
2001年 | 137篇 |
2000年 | 137篇 |
1999年 | 123篇 |
1998年 | 26篇 |
1997年 | 34篇 |
1996年 | 25篇 |
1995年 | 19篇 |
1994年 | 14篇 |
1993年 | 17篇 |
1992年 | 41篇 |
1991年 | 36篇 |
1990年 | 45篇 |
1989年 | 33篇 |
1988年 | 36篇 |
1987年 | 33篇 |
1986年 | 26篇 |
1985年 | 23篇 |
1984年 | 16篇 |
1983年 | 12篇 |
1979年 | 19篇 |
1977年 | 9篇 |
1976年 | 11篇 |
1975年 | 8篇 |
1974年 | 8篇 |
1972年 | 9篇 |
1971年 | 7篇 |
1970年 | 7篇 |
1967年 | 6篇 |
排序方式: 共有4432条查询结果,搜索用时 0 毫秒
1.
2.
3.
José Abal Arca Isaura Parente Lamelas Raquel Almazán Ortega José Blanco Pérez María Elena Toubes Navarro Pedro Marcos Velázquez 《Archivos de bronconeumologia》2009,45(10):502-507
Background and objectiveTo analyse frequency, characteristics and patient survival with lung cancer (LC) and Common Obstructive Pulmonary Disease (COPD), comparing them with patients that do not have COPD.Material and methodsA retrospective study, of patients diagnosed by means of cytohistology. Survival was estimated by the Kaplan-Meier method. Statistical analysis was carried out using SPSS 15.0.ResultsA total of 996 patients were diagnosed, 39.8% with COPD. Mean age70±9.19 years. GOLD stages: I 18.2%, II 53.6%, III 24%, IV 4.2%. The histological types: squamous cell carcinoma 48.2%, adenocarcinoma 22%, and small cell carcinoma 22.5%. Survival was longer in the COPD group.ConclusionsLC and COPD are combined in 39.8%. Squamous cell type is more frequent and survival was longer in the COPD group. 相似文献
4.
David Jiménez Castro Gema Díaz David Martí Carlos Escobar Javier Ortega Sergio García-Rull Joaquin Picher Antonio Sueiro 《Blood coagulation & fibrinolysis》2007,18(2):173-177
This study aimed to determine whether a weight-adjusted dose of subcutaneous enoxaparin is as effective and safe as oral acenocoumarol for the secondary prophylaxis of pulmonary embolism. Three hundred and eighty consecutive noncancer outpatients hospitalized with an episode of symptomatic pulmonary embolism selected treatment with acenocoumarol or enoxaparin at a dose of 1 mg/kg once daily after being informed of the type of administration and expected frequency of laboratory monitoring for both medicinal products. Endpoints were symptomatic recurrent thromboembolic events evaluated by standard objective testing, and a composite endpoint of recurrent venous thromboembolism, major bleeding, and death from any cause. One hundred and ninety-nine patients (52%) chose acenocoumarol therapy and 181 chose enoxaparin monotherapy. Four patients in the enoxaparin group (2.2%) and six patients in the acenocoumarol group (3%) had an objective thromboembolic recurrence (hazard ratio, 1.35; 95% confidence interval, 0.38-4.79; P = 0.64). Nine patients in the enoxaparin group (5.0%) had a hemorrhagic complication compared with 11 in the acenocoumarol group (5.5%) (P = 0.81). The hospital length of stay was shorter with enoxaparin compared with acenocoumarol (11 versus 16 days, P = 0.0001). Enoxaparin is as effective and safe as acenocoumarol in the secondary prevention of recurrent thromboembolic disease and is associated with shorter hospitalization. 相似文献
5.
6.
7.
8.
Jose M. Benitez Del Castillo Ignacio Jimenez-Alfaro Pilar Ortega Alfredo Castillo David Diaz Nicolas Toledano Julian Garcia-Sanchez 《Documenta ophthalmologica. Advances in ophthalmology》1994,86(4):387-393
The possible beneficial effects on the lens and retina which Bendazac Lysine may have in the treatment of adult diabetic patients were investigated. Twenty patients, ranging in age from 54.80 ± 5.86 years old, were studied. The average duration of the diabetes was 11.32 ± 4.10 years. Thirteen patients had background retinopathy. The metabolic controls carried out during the study were satisfactory (HbA1<11%). Bendazac Lysine (500 mg three times a day) was administered for 6 months. Blood-retinal barrier permeability (VPR and VPRt) and lens transmittance (t) were evaluated prior to and 6 months after treatment by fluorophotometry. No statistically significant differences between the pre- and post-treatment values of the retina permeability were observed, however, there was a statistically significant improvement (p<0.05) (initial value: t= 0.813 ± 0.040 and final value: t=0.823 ± 0.037) in the lens transmittance. The authors conclude that Bendazac Lysine has a beneficial effect on the lens in the diabetic adult although no improvement in the permeability of the blood-retinal barrier has been observed. 相似文献
9.
M R Hamre L L Robison M E Nesbit H N Sather A T Meadows J A Ortega G J D'Angio G D Hammond 《Journal of clinical oncology》1987,5(11):1759-1765
The Childrens Cancer Study Group has assessed serum follicle-stimulating hormone (FSH), luteinizing hormone (LH), and pubertal development in 97 long-term female survivors of childhood acute lymphoblastic leukemia (ALL). All patients received identical induction and maintenance therapy with either 18 or 24 Gy of radiation therapy (RT) to one of the following fields: cranial, craniospinal, or craniospinal plus 12 Gy abdominal RT including the ovaries. Thirty-six percent (35 patients) were found to have above normal levels of FSH and/or LH. The percentages of elevated values for RT fields were 93% for craniospinal plus abdominal RT, 49% for craniospinal RT, and 9% for cranial RT (P less than .001). A dose-response relationship was observed between 18 Gy and 24 Gy in females receiving only craniospinal RT (P = .01). Craniospinal plus abdominal RT and abnormal FSH/LH levels were significantly associated with lack of pubertal development and delayed onset of menses. Duration of maintenance chemotherapy was not associated with abnormal gonadotropin levels or the development of secondary sexual characteristics. Additional follow-up of this cohort is needed to establish the ultimate pubertal development and fertility of these patients. 相似文献
10.
Ana Ortega Ph.D. George Dranitsaris M.Sci.Phm. Jeremy Sturgeon M.D. Heather Sutherland M.Sci. Amit Oza M.D. 《Gynecologic oncology》1997,66(3):454-463
The standard treatment for patients with advanced ovarian cancer (AOC) has been cyclophosphamide and cisplatin (CP). Recently, the results of a large randomized comparative trial demonstrated that the combination of paclitaxel and cisplatin (TP) provided a progression-free survival benefit of 5 months. In this study, a cost–utility analysis was performed from a Canadian health care system perspective to estimate the incremental cost-effectiveness of the TP combination. Twelve AOC patients who received treatment with TP were matched for age and disease stage on a 1-to-2 basis with a CP control. Total hospital resource consumption was then collected for all patients. Treatment preferences were estimated from a cohort of 20 patients and 40 healthy female volunteers using the time trade-off technique. The outcomes were then generated through a decision-analytic model. First-line treatment costs with TP were approximately fourfold greater on a per-cycle basis than the CP alternative (Can$1911 vs Can$459). When progression-free survival benefit and patient treatment preferences were incorporated into the analysis, the results of the decision model revealed an incremental cost between Can$12,000 and Can$24,000 per quality-adjusted progression-free year with the TP protocol. Even though the TP combination has a considerably higher drug acquisition cost, the results of the current analysis suggest that this new chemotherapy regimen does provide patients with substantial quality-adjusted progression-free survival benefit at a reasonable cost to the Canadian health care system. 相似文献